CDTX Cidara Therapeutics

Cidara Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Cidara Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020.

Presentation Information:
Date:Tuesday, August 11, 2020
Time:3:30 PM ET
Webcast:A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at .

About Cidara Therapeutics

Cidara is developing long-acting therapeutics to improve the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit .

INVESTOR CONTACT:

Brian Ritchie

LifeSci Advisors

(212) 915-2578

MEDIA CONTACT:

Karen O’Shea, Ph.D.

LifeSci Communications

(929) 469-3860

 

EN
04/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cidara Therapeutics

 PRESS RELEASE

Cidara Therapeutics Provides Corporate Update and Reports Second Quart...

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results Phase 2b NAVIGATE clinical trial evaluating CD388 for the prevention of seasonal influenza met primary and all secondary efficacy endpoints for all dose groupsEnd of Phase 2 meeting request submitted to the U.S. Food and Drug Administration (FDA)Closed upsized public offering for gross proceeds of $402.5 million; significantly strengthened balance sheet to conduct planned Phase 3 program for CD388Added to Russell 2000® and Russell 3000® IndexesConference call and webcast today at 5:00 PM Eastern ...

 PRESS RELEASE

Cidara Therapeutics to Report Second Quarter 2025 Financial Results an...

Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025 SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its second quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, August 7, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss t...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: July 19, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: July 12, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: July 5, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch